Friday, August 2, 2019

Strong Growth In New Drugs Propelling Roche

Roche (OTCQX:RHHBY) needed a good second quarter and management delivered, with the company’s portfolio of new pharmaceuticals helping drive double-digit growth for the drug business and high single-digit growth for the business overall. Better still, the pipeline remains stocked with opportunities, and the company should average about one major read-out a month for the next 18 months.

Valuation remains attractive, particularly in light of upgraded near-term expectations. Fair value remains in the mid-$30s, and management indicated that a higher dividend should be on the way.

Continue here:
Strong Growth In New Drugs Propelling Roche

No comments: